The effects of luminescent ruthenium(II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling

Biomaterials

Volumn 34, Issue 1, 2013, Pages 171-180

  Sun, Dongdong ^a   Liu, Yanan ^a,b   Yu, Qianqian ^a   Zhou, Yanhui ^a   Zhang, Rong ^a   Chen, Xiaojia ^a   Hong, An ^a   Liu, Jie ^a  

^a JINAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiogenesis; Ru(II) polypyridyl complexes; Selenium; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS; ANTI-CANCER THERAPIES; BLOOD SUPPLY; CELLULAR UPTAKE; CHICKEN CHORIOALLANTOIC MEMBRANES; DRUG CANDIDATES; FLUORESCENCE CONFOCAL MICROSCOPY; FUNCTIONALIZED; HUVEC CELLS; IN-VIVO; LUMINESCENT RUTHENIUM; PROTEIN KINASE; SELENIUM NANOPARTICLES; SURAMIN; TUBE FORMATION; TUMOR ANGIOGENESIS; TUMOR GROWTH; VASCULAR ENDOTHELIAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

CAMS; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG THERAPY; ENDOTHELIAL CELLS; LUMINESCENCE; NANOPARTICLES; RUTHENIUM; TUMORS;

SELENIUM;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; LUMINESCENT AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RUTHENIUM MODIFIED SELENIUM NANOPARTICLE; SELENIUM NANOPARTICLE; SURAMIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHICK EMBRYO; CHORIOALLANTOIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; EMBRYO; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN UMBILICAL VASCULAR ENDOTHELIAL CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM;

ANIMALS; ANNEXIN A5; APOPTOSIS; CELL MOVEMENT; CELL SURVIVAL; CHICKENS; CHORIOALLANTOIC MEMBRANE; CIRCULAR DICHROISM; ENDOCYTOSIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; HEP G2 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUMINESCENT MEASUREMENTS; MAP KINASE SIGNALING SYSTEM; NANOPARTICLES; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROPHASE; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RUTHENIUM; SELENIUM;

EID: 84868093130     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.031     Document Type: Article

References (30)

1. Willett C.G., Boucher Y., Di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
2. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
3. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature (London) 2000, 407:249-257.
4. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
5. Gurunathan S., Lee K.J., Kalishwaralal K., Sheikpranbabu S., Vaidyanathan R., Eom S.H. Antiangiogenic properties of silver nanoparticles. Biomaterials 2009, 30:6341-6350.
6. Mendel D.B., Schreck R.E., West D.C., Li G., Strawn L.M., Tanciongco S.S., et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 2000, 6:4848-4858.
7. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006, 312:594-607.
8. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-ascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
9. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
10. Manetti F., Corelli F., Botta M. Fibroblast growth factors and their inhibitors. Curr Pharm Des 2000, 6:1897-1924.
11. Kathir K.M., Kumar T.K.S., Yu C. Understanding the mechanism of the antimitogenic activity of suramin. Biochemistry 2006, 45:899-906.
12. Gordon M.S., Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005, 69:25-33.
13. Gielen M. Review: organotin compounds and their therapeutic potential: a report from the organometallic chemistry department of the free university of brussels. Appl Organomet Chem 2002, 16:481-494.
14. Wilbuer A., Vlecken D.H., Schmitz D.J., Kräling K., Harms K., Bagowski C.P., et al. Iridium complex with antiangiogenic properties. Angew Chem Int Ed 2010, 49:3839-3842.
15. Nowak-Sliwinska P., van Beijnum J.R., Casini A., Nazarov A.A., Wagnieres G., Van den Bergh H., et al. Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem 2011, 54:3895-3902.
16. Portney N.G., Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 2006, 384:620-630.
17. Liu H., Webster T.J. Nanomedicine for implants: a review of studies and necessary experimental tools. Biomaterials 2007, 28:354-369.
18. Valdiglesias V., Pásaro E., Méndez J., Laffon B. In vitro evaluation of selenium genotoxic, cytotoxic, and protective effects: a review. Arch Toxicol 2010, 84:337-351.
19. Elmes R.B.P., Erby M., Cloonan S.M., Quinn S.J., Williams D.C., Gunnlaugsson T. Quaternarized pdppz: synthesis, DNA-binding and biological studies of a novel dppz derivative that causes cellular death upon light irradiation. Chem Commun 2011, 47:686-688.
20. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973, 179:588-590.
21. Sun D., Liu Y., Liu D., Zhang R., Yang X., Liu J. Stabilization of G-quadruplex DNA, inhibition of telomerase activity and live cell imaging studies of chiral ruthenium(II) complexes. Chem Eur J 2012, 18:4285-4295.
22. 6-arene ruthenium complexes with 1,10-phenanthroline-derived ligands. Dalton Trans 2011, 41:1734-1741.
23. Elmes R.B.P., Orange K.N., Cloonan S.M., Williams D.C., Gunnlaugsson T. Luminescent ruthenium(II) polypyridyl functionalized gold nanoparticles; their DNA binding abilities and application as cellular imaging agents. J Am Chem Soc 2011, 133:15862-15865.
24. Jun Y., Lee J.H., Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed 2008, 47:5122-5135.
25. Alivisatos A.P., Gu W., Larabell C. Quantum dots as cellular probes. Annu Rev Biomed Eng 2005, 7:55-76.
26. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
27. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., et al. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
28. Feng Y., Li M., Wang B., Zheng Y.G. Discovery and mechanistic study of a class of protein arginine methylation inhibitors. J Med Chem 2010, 53:6028-6039.
29. Ganesh V.K., Muthuvel S.K., Smith S.A., Kotwal G.J., Murthy K.H.M. Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein. Biochemistry 2005, 44:10757-10765.
30. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.